NorthWest Biotherapeutics Inc (NWBO)

[iclight]

The Jama data shows mOS went down when they removed the control group. Do you not understand that is bad for the trial? And shills will claim "look at the long tail". GBM is a long tail disease. That long tail consists of prognostic factors that were excluded from much of the ECA which didn't even have patient level data to compare. It showed in the IMUC and CLDX data too. But it also showed in those trial's control arms because they were of the same patient population.

Keep attacking those who actually understand the data simply because you don't.